Surgery in patients with inherited bleeding disorders

Anaesthesia

Volumn 70, Issue Suppl. 1, 2015, Pages 112-120

  Mensah, P K ^a   Gooding, R ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING DISORDER; BLOOD LOSS, SURGICAL; COMPLICATION; HEMOPHILIA A; HUMAN; POSTOPERATIVE CARE; PREOPERATIVE CARE; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD LOSS, SURGICAL; HEMOPHILIA A; HUMANS; POSTOPERATIVE CARE; PREOPERATIVE CARE; VON WILLEBRAND DISEASES;

EID: 84925223499     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/ANAE.12899     Document Type: Article

References (48)

1. Hay CRM, Palmer B, Dewhurst L. UK Haemophilia Centre Doctors’ Organisation. Bleeding Disorders Statistics for April 2009 to March 2010. www.ukhcdo.org/docs/AnnualReports/2010/UKHCDO%20Bleeding%20Disorder%20Statistics%20for%202009-2010.pdf (accessed 03/08/2014).
2. Escobar MA, Maahs J, Hellman E, et al. Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: Perspectives and best practices derived from experienced treatment centres. Haemophilia 2012; 18: 971-81.
3. Dormandy KM. Pre-operative investigation and management during surgery of patients with bleeding disorders. Annals of the Royal College of Surgeons of England 1971; 48: 26-7.
4. Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: Literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
5. Mackie I, Cooper P, Lawrie A, Kitchen S, Gray E, Laffan M. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. 2012. http://www.bcshguidelines.com/documents/assay_guideline_2012.pdf (accessed 25/08/ 2014).
6. Mannucci PM. Hemostatic drugs. New England Journal of Medicine 1998; 339: 245-53.
7. Tsoukas C, Eyster ME, Shingo S. Evaluation of the efficacy and safety of etoricoxib in the treatment of haemophilic arthropathy. Blood 2006; 107: 1785-90.
8. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
9. Aryal KR, Wiseman D, Siriwardena AK, Bolton-Maggs PH, Hay CR, Hill J. General Surgery in patients with a bleeding diathesis: How we do it. World Journal of Surgery 2011; 35: 2603-10.
10. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
11. Katz J. Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large scale North American survey. Haemophilia 1996; 2: 28-31.
12. Mannucci PM. Desmopressin: A non transfusional agent. Annual Review of Medicine 1990; 41: 55-64.
13. Mannucci PM, Pareti FI, Ruggeri ZM, Capitanio A. 1-deamino- 8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrand disease. Lancet 1977; 309: 869-72.
14. Dunn AL, Powers JR, Ribeiro MJ, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand’s disease: A case report and review of 40 patients. Haemophilia 2000; 6: 11-4.
15. Duthie RB, PLF, Dodd CAF. Reconstructive surgery and joint replacement. In: Duthie RB, Rizza CR, Giangrande PLF, Dodd CAF, ed. The Management of Musculoskeletal Problems in the Haemophilias, 2nd sub edn. Oxford: Oxford University Press, 1994: 191-215.
16. Dimichelle D, Negrier C. A retrospective post licensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
17. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive surgical procedures in patients with severe haemophilia A or B with inhibitors. Journal of Pediatric Hematology and Oncology 2007; 29: 216-21.
18. Rangarajan S, Yee TT, Wilde J. Experience of four UK comprehensive care centres using FEIBA for surgeries in patients with inhibitors. Haemophilia 2011; 17: 28-34.
19. Obergfell A, Auvinen MK, Mathew P. Recombinant activated VII for haemophilia patients with inhibitors undergoing orthopaedic surgery: A review of the literature. Haemophilia 2008; 14: 233-41.
20. Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: Practical aspects. Haemophilia 2013; 19: 2-10.
21. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-9.
22. Manucci PM, Franchini M, Castaman G, et al. Italian Association of Haemophilia Centres. Evidence-based recommendations on the treatment of von Willebrand’s disease in Italy. Blood Transfusion 2009; 7: 117-26.
23. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by genotype and phenotype in type 1 von Willebrand’s disease (VWD): Results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-9.
24. Witmer CM, Elden L, Butler RB, Manno CS, Raffini LJ. Incidence of bleeding complications in pediatric patients with type 1 von Willebrand’s disease undergoing adenotonsilar procedures. Journal of Pediatrics 2009; 155: 68-72.
25. Shah SB, Lalwani AK, Koerper MA. Peri-operative management of von Willebrand’s disease in otolaryngologic surgery. Laryngoscope 1998; 108: 32-6.
26. Roizen MF. More preoperative assessment by physicians and less by laboratory tests. New England Journal of Medicine 2000; 342: 204-5.
27. Burk CD, Muller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics 1992; 89: 691-5.
28. Suchman AL, Mushlin AI. How well does the activated partial thromboplastin time predict postoperative hemorrhage? Journal of the American Medical Association 1986; 256: 750-3.
29. Bowie EJ, Owen CA. The significance of abnormal preoperative haemostatic tests. Progress in Hemostasis and Thrombosis 1980; 5: 179-209.
30. Narr BJ, Warner ME, Shroeder DR, et al. Outcomes of patients with no laboratory assessment before anaesthesia and a surgical procedure. Mayo Clinic Proceedings 1997; 72: 505-9.
31. Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV. Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954?Leu substitution in the factor VIII A3 domain. British Journal of Haematology 1999; 105: 1123-6.
32. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010; 30: 207-11.
33. Peyvandi F, Palla R, Menegatti M, et al. On behalf of the European Network of rare bleeding disorders group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: Results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis 2012; 10: 615-21.
34. Peyvandi F, Bolton-Maggs PH, Batorova A, et al. Rare bleeding disorders. Haemophilia 2012; 18: 148-53.
35. Chee YL, Crawford JC, Watson HG, et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Journal of Haematology 2008; 140: 496-504.
36. Bolton-Maggs PHB. The rare coagulation disorders. Treatment of Haemophilia 2006; 39. http://haemophilia.ie/PDF/Rare%20coagulation%20disorders.pdf (accessed 04/09/2014).
37. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thrombosis and Haemostasis 1995; 74: 1597-603.
38. O’Brien SH. Bleeding scores: Are they really useful? Blood American Society of Hematology Education Program 2012; 2012: 152-6.
39. George JN, Caen JP, Nurden AT. Glanzmann’s thrombasthenia: The spectrum of clinical disease. Blood 1990; 75: 1383-95.
40. Perry DJ, Fitzmaurice DA, Kitchen S, et al. Point-of-care testing in haemostasis. British Journal of Haematology 2010; 150: 501-14.
41. Cattaneo M, Cerletti C, Harrison P, et al. Recommendations for the standardization of light transmission aggregometry: A consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. Journal of Thrombosis and Haemostasis 2013; 11: 1183-9.
42. Nurden AT, Freson K, Seligson U. Inherited platelet disorders. Haemophilia 2012; 18: 154-60.
43. Santoro C, Rago A, Biondo F, et al. Prevalence of allo-immunization anti-HLA and anti-integrin aIIbb3 in Glanzmann’s Thrombasthenia patients. Haemophilia 2010; 16: 805-12.
44. Almeida AM, Khair K, Hann I, et al. The use of recombinant factor VIIa in children with inherited platelet function disorders. British Journal of Haematology 2003; 121: 477-81.
45. Bolton-Maggs PHB, Chalmers EA, Collins PW, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. British Journal of Haematology 2006; 135: 603-33.
46. The Australian Haemophilia Centre Doctors Organisation Guidelines for the management of patients with haemophilia undergoing surgical procedures. 2005. www.ahcdo.org.au/publications/cid/1/parent/0/t/publications/parent_name/Guildelines (accessed 25/08/2014).
47. rd edn. Oxford: John Wiley & Sons Ltd, 2014.
48. CSL Behring GMBH. Clinical Pharmacology Review. 2010. www.fda.gov/downloads/BiologicsBloodVaccines/BloodBlood-Products/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM246749.pdf (accessed 04/09/2014).